Neurocrine Biosciences | Себестоимость



Cost Of Sales Изменить Дата
AbbVie USD 4B 394M 2025-03
Acadia Pharmaceuticals USD 21.8M 2.95M 2024-12
Agios Pharmaceuticals USD 1.08M 175K 2025-03
ALKERMES USD 49.2M 12.92M 2025-03
Alnylam Pharmaceuticals USD 71.04M 31.78M 2025-03
Amgen USD 2.6B 507M 2025-03
Biogen USD 629.3M 45.8M 2025-03
BioMarin Pharmaceutical USD 151.56M 15.42M 2025-03
Cytokinetics 463K 79.14M 2024-09
Dynavax Technologies USD 13.41M 326K 2024-12
Exelixis USD 19.96M 2.64M 2025-01
Gilead Sciences USD 1.54B 41M 2025-03
Halozyme Therapeutics USD 42.06M 7.37M 2024-12
Incyte USD 67.8M 14.58M 2025-03
Ionis Pharmaceuticals USD 1000K 2.83M 2025-03
Neurocrine Biosciences USD 9.3M 1.3M 2024-12
Pfizer USD 2.59B 3.06B 2025-03
Prothena 970K 4.78M 2024-09
Regeneron Pharmaceuticals USD 265.5M 299.9M 2025-03
Repligen USD 78.41M 8.82M 2025-03
Sarepta Therapeutics USD 132.3M 40.61M 2024-12
Teva Pharmaceutical Industries USD 2.11B 18M 2024-12
Ultragenyx Pharmaceutical USD 16.89M 4.13M 2024-12
Vertex Pharmaceuticals USD 423.4M 30.8M 2024-12



Neurocrine Biosciences Себестоимость - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - May 2025.